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Abstract 
Background: HIV-1 integrase is the target for three FDA-approved drugs, raltegravir, elvitegravir, and dolutegravir. All 
three drugs bind at the active site of integrase and block the strand transfer step of integration. We previously showed 
that sub-optimal doses of the anti-HIV drug raltegravir can cause aberrant HIV integrations that are accompanied by a 
variety of deletions, duplications, insertions and inversions of the adjacent host sequences.
Results: We show here that a second drug, elvitegravir, also causes similar aberrant integrations. More importantly, 
we show that at least two of the three clinically relevant drug resistant integrase mutants we tested, N155H and 
G140S/Q148H, which reduce the enzymatic activity of integrase, can cause the same sorts of aberrant integrations, 
even in the absence of drugs. In addition, these drug resistant mutants have an elevated IC50 for anti-integrase drugs, 
and concentrations of the drugs that would be optimal against the WT virus are suboptimal for the mutants.
Conclusions: We previously showed that suboptimal doses of a drug that binds to the HIV enzyme integrase and 
blocks the integration of a DNA copy of the viral genome into host DNA can cause aberrant integrations that involve 
rearrangements of the host DNA. We show here that suboptimal doses of a second anti-integrase drug can cause 
similar aberrant integrations. We also show that drug-resistance mutations in HIV integrase can also cause aberrant 
integrations, even in the absence of an anti-integrase drug. HIV DNA integrations in the oncogenes BACH2 and MKL2 
that do not involve rearrangements of the viral or host DNA can stimulate the proliferation of infected cells. Based on 
what is known about the association of DNA rearrangements and the activation of oncogenes in human tumors, it is 
possible that some of the deletions, duplications, insertions, and inversions of the host DNA that accompany aberrant 
HIV DNA integrations could increase the chances that HIV integrations could lead to the development of a tumor.
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Background
Integration of a DNA copy of the genome of the virus 
into a host chromosome is an essential step in the retro-
viral life cycle. Retroviral DNA integration is a two-step 
process, which begins after the viral enzyme reverse tran-
scriptase synthesizes a DNA copy of the viral genome. In 
the first step, termed 3′ processing, the virally encoded 
enzyme integrase (IN) binds to and removes two nucleo-
tides from the 3′ ends of the linear viral DNA. The INs 
that are bound at the two ends of the viral DNA interact 
and the resulting IN tetramer (or octamer) holds the 3′ 
ends of the viral DNA near each other so that they come 
into close contact with the host DNA. In the second step, 
the strand transfer reaction, IN promotes an exchange 
reaction that inserts the newly exposed hydroxyl groups 
at the 3′ ends of the viral DNA into the two strands of 
host genome a few nucleotides apart. Host enzymes then 
repair the nicks in the host genome that are created by 
the insertion of the viral DNA, creating an integrated 
provirus. The positions at which these exchange reac-
tions occur on the host DNA generates, after the nicks 
are repaired, a short duplication of the host sequences 
that flank the provirus. The length of the duplication 
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in the host DNA depends on the geometry of the IN 
tetramer/octamer that inserts the two viral DNA ends 
and is characteristic of the type of retrovirus. The length 
varies from 4 to 6 base pairs (bp); HIV integration creates 
5 bp duplications [1–5].
IN inhibitors are the newest family of anti-HIV drugs to 
be approved for human use [6]. All of the approved anti-
IN drugs preferentially block the strand-transfer step of 
integration, and the drugs are, for that reason, called IN 
strand-transfer inhibitors, or INSTIs. INSTIs interact 
with both IN and the viral DNA substrate and chelate 
the two metal ions at the IN active site. Upon binding, 
INSTIs displace the dA at the very 3′ ends of viral DNA 
and have a π-stacking interaction with the penultimate 
nucleotide (dC) at both of the 3′ ends of the viral DNA 
[7–9].
We previously showed that suboptimal doses of the 
INSTI raltegravir (RAL) can lead to the generation of 
aberrant proviruses [10]. Generally speaking, these 
aberrant HIV integrations are quite similar to the aber-
rant integrations that arose in experiments done with 
avian sarcoma leukoisis virus (ASLV) vectors. In the 
ASLV experiments, one of the ends of the viral DNA was 
mutated in a way that caused it to be a poor substrate 
for IN-mediated integration [11, 12]. The “good” end of 
the viral DNA was integrated normally, by IN, whereas 
the second (mutant) end was apparently inserted by host 
enzymes. The host-mediated integration events led to the 
generation of rearrangements of the host DNA, including 
insertions, deletions, and more rarely, inversions, or in 
some cases, the transfer of sequences from one chromo-
some to another. The host-mediated insertions can also 
lead to deletions or insertions of viral DNA sequences 
at the 3′ ends of the proviral DNA. In experiments done 
with HIV-1, we showed that, if the concentration of RAL 
is suboptimal, it would, in some cases, block the IN-
mediated integration of one of the two ends of the viral 
DNA, causing aberrant integrations similar to those that 
arise when one end of the ASLV DNA was mutated.
HIV-1 DNA integration into certain host genes can 
cause the infected cells to divide and persist in patients 
[13, 14]. The fact that suboptimal doses of RAL can cause 
HIV integrations that led to significant rearrangements 
of the host genome, including the transfer of sequences 
from one chromosome to another, raises the concern that 
aberrant integrations that involve rearrangements of the 
host sequences might increase the odds of proliferation 
of an infected cell more than normal integrations [10]. 
For that reason, we tested whether other perturbations 
can cause similar aberrant integrations.
We show here that a suboptimal dose of a second INSTI 
that has been approved for use in humans, elvitegravir 
(EVG), can cause aberrant HIV-1 DNA integrations that 
are quite similar to the aberrant integrations caused by 
suboptimal doses of RAL. In addition, all anti-HIV drugs 
can select for resistance; INSTIs are not exceptional in 
this regard. Because INSTIs bind to the IN active site, the 
mutations that confer resistance to INSTIs are in or near 
the active site [8]. Generally speaking, any mutation in 
an HIV-encoded protein is likely to have some negative 
impact on the ability of the virus to replicate. However, 
the regions in and around the active sites of the virally 
encoded enzymes are particularly well conserved, and it 
is not surprising that amino acid substitutions in or near 
the active sites, including drug-resistance mutations, are 
often deleterious. Some of the INSTI-resistance muta-
tions that are selected because they confer resistance to 
INSTIs are known to have a considerable negative impact 
on the ability of IN to integrate viral DNA, and on viral 
titer. Drug-induced selection for mutations that signifi-
cantly impact the fitness of the virus are generally consid-
ered beneficial for patients; however, that may not always 
be the case.
We considered the possibility that some of the INSTI-
resistance mutations could mimic the effects of a sub-
optimal dose of either RAL or EVG to the extent that 
they might reduce the ability of IN to insert the ends of 
the viral DNA efficiently. Thus, the reduction in the enzy-
matic activity of IN caused by these mutations might be 
sufficient, by itself, to lead to the generation of aberrant 
proviruses, even in the absence of an added drug. We 
tested the effects of three IN mutations, Y143R, N155H, 
and the double mutation G140S/Q148H, all of which 
reduce the susceptibility of HIV-1 to RAL [15], on viral 
DNA integration. Two of these mutants, N155H and 
G140S/Q148H, also had, relative to WT HIV-1, a reduced 
susceptibility to EVG, and to other INSTIs. Viruses that 
carry these IN mutations replicate less efficiently than 
WT [16–19] (Unpublished observations). In the absence 
of RAL, infection with a vector that carries two of these 
three IN mutants led to a significant increase in aber-
rant integrations. These aberrant proviruses have struc-
tures that are similar to those that arise upon treatment 
of the WT virus with suboptimal doses of RAL or EVG. 
As might be expected, the addition of RAL appeared to 
increase the fraction of aberrant proviruses that arose 
during infections with all three of the IN mutants, 
although the differences we saw in the presence of RAL 
were not statistically significant. These results raise addi-
tional concerns. First, even in the absence of an IN inhib-
itor, mutations in IN that are selected by treatment with 
an INSTI can reduce IN enzymatic activity, and this can 
cause aberrant integrations. Second, because IN muta-
tions make the doses of INSTIs that can be administered 
to patients suboptimal, treating an infection in which the 
virus carries INSTI-resistance mutations with an INSTI 
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A four-vector system was used to generate the virus 
stocks. A ClaI–MluI shuttle cassette that contains 
sequences that permit the replication of circular forms 
of viral DNA as plasmids in Escherichia coli was derived 
from pHIV-SH [20]. The cassette was shortened by 
removing the Pol II promoter. The final cassette con-
tained a zeocin resistance gene with an upstream EM-7 
Promoter (EM-zeo), a lac operator sequence, and a ColE1 
origin of replication (oriE). A coding region for enhanced 
green fluorescent protein (eGFP), under the control of 
the cytomegalovirus promoter (CMV), was inserted 
as a NotI–ClaI fragment immediately upstream of the 
plasmid-recovery cassette. The plasmid used to produce 
the viral RNA, pSICO-LZF, was derived from pSICO-
XBX by inserting the shuttle cassette and the eGFP cod-
ing region as a NotI–MluI fragment [21]. The viral RNA 
was expressed from a chimeric 5′ LTR with a CMV pro-
moter in place of U3, and the vector also contained an 
HIV Psi packaging sequence and a Rev Response element 
(RRE)/RNA export signal [22]. The four-vector system 
included, in addition to pSICO-LZF, a plasmid expressing 
HIV-1 Gag and Gag–Pol: pMDL-SH.IN+; a plasmid that 
expresses REV: pRSV-REV; and a plasmid that expresses 
VSV-G: pCMV-VSV-G. pMDL-SH.IN+ was derived 
from pMDLg/pRRE by replacing the gag and pol genes 
with the equivalent sequences from pHIV-SH [20]. Both 
the pRSV-REV and the parental pMDLg/pRRE expres-
sion plasmids were obtained from Didier Trono (École 
Polytechnique Fédérale de Lausanne, Lausanne, Switzer-
land) through Addgene, Inc. [22]. The three IN mutants 
used in the experiments have been described [15]. The 
segments carrying the mutant forms of IN were moved 
into the pMDL-SH.IN+ plasmid by transferring the seg-
ment of the Gag–Pol coding sequence between PstI and 
AflII from pNLNgoMIVR-ΔEnv.Luc into pMDL-SH.IN+ 
using the corresponding restriction enzyme sites.
Cells, transfection, and infection
Human embryonic kidney (HEK) 293T and human oste-
osarcoma (HOS) cells were maintained in DMEM (Cell-
gro) supplemented with 5 % (vol/vol) FBS, 5 % (vol/vol) 
newborn calf serum, 100 U/mL penicillin G, and 100 µg/
mL streptomycin (Quality Biological). Recombinant virus 
stocks were generated by calcium phosphate-mediated 
cotransfection of 293T cells seeded at 1.5  ×  106  cells 
in 100-mm culture plates with the plasmids that make 
up the four-vector system. Thirteen micrograms of 
pSICO-LZF (or pSICO-LZR), 12  µg pMDL-SH.IN+, 
5 µg pRSV-REV, and 4 µg pCMV-VSV-G were used per 
plate.  6  h after transfection, cells were gently washed 
three times with PBS, and fresh media was added. Virus-
containing supernatants were harvested 48 h after trans-
fection, clarified by centrifugation at 1620×g for 10 min, 
and incubated at 37  °C with 500  U of DNase I (Invit-
rogen) per 50  mL virus in 5  mM MgCl2 to remove any 
residual vector DNA carried over from the transfection. 
HOS cells were seeded at 7.5  ×  105 per 100-mm plate 
the day before infection. Peripheral blood mononuclear 
cells (PBMCs) from healthy human donors were seeded 
at a minimum of 5  ×  106 cells per 25-cm2 cell culture 
flask (Corning) and maintained in RPMI media supple-
mented with 10 % FBS, 100 U/mL penicillin G, 100 µg/
mL streptomycin, 2  mM  l-glutamine, and 50 U IL-2. 
The PBMCs were activated with 5  µg/mL phytohemag-
glutinin-P (PHA-P) for 48–72 h. The cells were then col-
lected by centrifugation and resuspended in fresh media 
containing IL-2. Drug-free cells were infected with 50 ng/
mL p24 recombinant virus in the presence of 4 µg/mL of 
polybrene (Sigma-Aldrich). The cells that were treated 
with various suboptimal doses of RAL (a gift from Daria 
Hazuda, Merck Research Laboratories, West Point, PA) 
or EVG [23] were preincubated with the drug for 3 h at 
37 °C and then infected with 50 ng/mL p24 recombinant 
virus in the presence of 4 µg/mL of polybrene. The appro-
priate concentration of RAL or EVG was maintained dur-
ing the infection. After 24 h of incubation with the virus, 
the virus-containing media was removed and replaced 
with fresh media (without virus) in the drug-free cells, 
whereas fresh media (without virus) containing the 
appropriate concentrations of RAL or EVG was added 
to the drug-treated cells. The cells were harvested 4 days 
after infection, and DNA was extracted using the QIAmp 
DNA Blood Kit from Qiagen.
Recovery of integrated retroviral DNA
Genomic DNAs (100 µg) isolated from the infected HOS 
cells or PBMCs were treated with DpnI for 2 h at 37  °C 
to eliminate any remaining plasmid DNA that might 
have been carried over from the transfection. The DpnI-
digested DNA was heated at 80  °C for 20 min and then 
ethanol precipitated. The DNA was digested overnight 
with BclI at 50 °C, extracted with phenol/chloroform, and 
ethanol precipitated. DNA was resuspended in 890  µL 
of nuclease-free water and was self-ligated overnight 
at 16  °C in the presence of T4 DNA Ligase and ligation 
buffer (NEB) in a final volume of 1 mL. The mix was etha-
nol precipitated and resuspended in 100 µL of nuclease-
free water.
DNA (up to 700 ng) was introduced into ElectroMAX 
DH10B E. coli cells by electroporation using the BTX 
Electroporation System at 186  Ω and 2.5-kV resistance. 
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The bacterial cells were allowed to recover in 500  µL 
supra optimal broth with catabolite repression (SOC) 
media for 1.5  h at 37  °C with shaking, and plated on 
L-broth plates containing 100  µg/mL zeocin. The next 
day, colonies were picked and grown overnight in L-broth 
containing 100  µg/mL zeocin. DNA was purified using 
the Qiagen BIO ROBOT Universal System.
Sequencing of the integrated viral DNA
Recovered plasmids were directly sequenced using the 
primers LTR-FOR (5′ GACTTACAAGGCAGCTGTAG), 
which hybridizes to the vector genome in a region that 
just precedes the poly purine tract (PPT), and pSICO 
REV (5′ GCCTCTTGCCGTGCGCGCTTC), which 
hybridizes near the primer binding site (PBS), between 
the LTR and gag. All sequencing was performed by Mac-
rogen (Rockville, MD). In some cases the proviruses had 
sustained such large deletions that it was necessary to use 
additional primers to do additional sequencing to deter-
mine the end of the provirus. Human and viral sequences 
were analyzed by BLAST.
Results
Suboptimal doses of elvitegravir (EVG) can cause aberrant 
integration of HIV‑1 DNA
We previously showed that infecting cells in the pres-
ence of suboptimal doses of RAL can cause aberrant 
HIV-1 integrations, and we proposed that this was the 
result of the drug blocking the IN-mediated insertion of 
only one of the two ends of the viral DNA. If that view 
is correct, a suboptimal dose of any INSTI should cause 
similar aberrant integrations. Broadly speaking, the 
results we obtained with suboptimal doses of EVG were 
quite similar to the results we previously obtained with 
RAL. In both sets of experiments, we used an HIV-based 
viral vector that was generated using a 4-plasmid system 
(see “Methods” section and Additional file 1: Figure S1). 
There are advantages in using a one-round vector to do 
the experiments we report here. First, one-round vectors 
are safer than replication-competent HIV-1, particularly 
if drug-resistant mutants are being used in the experi-
ments. Second, if a one round vector is used, it is rela-
tively easy to prepare stocks that have a similar amount 
of infectious virus present. More importantly, if the 
experiments involve mutant viruses that grow at differ-
ent rates, differential replication will not affect the rela-
tive amounts of the viruses that are present throughout 
the experiment. Third, there can be no question that the 
virus could have reverted during the course of the experi-
ment. Fourth, it is much easier to accurately measure the 
impact of a given dose of an inhibitor in an experiment 
that uses single-round as opposed to a multi-round vec-
tors. In addition, integration of the vector DNA is carried 
out by normally by IN, and we showed that the replica-
tion of wild-type and drug-resistant versions of these 
vectors respond accurately and appropriately to a variety 
of INSTIs, including RAL, EVG, and dolutegravir (DTG) 
[9, 15, 24–28]. Finally, we previously used these vectors 
to show that RAL can cause aberrant integrations [10].
Viral DNAs were recovered from HOS cells infected 
with the HIV vector in the presence of suboptimal doses 
of EVG and sequenced with HIV-1 specific primers as 
described previously [10]. Before we began doing experi-
ments perturbing HIV integration, it was known that 
normal HIV-1 integration produces proviruses that have 
each of the LTRs inserted into the host genome with a 
loss of 2 bp from each end, and that the integrated pro-
viruses are flanked by a 5 bp repeat of the host DNA. To 
show that we could reproduce these results using our 
vector system, we previously showed that all 99 of the 
proviruses we recovered from an unperturbed infection 
of HOS cells with the WT vector were normal [10]. We 
got similar results when we infected PBMCs; none of the 
85 proviruses we isolated were aberrant. We have used 
the data from these WT vector controls to calculate the 
statistical significance of the integration site data we pre-
sent here.
As we previously reported for suboptimal doses of 
RAL, the addition of suboptimal doses of EVG led to the 
recovery of aberrant proviruses when the infections were 
done with a vector that carried WT IN (Table 1). We also 
recovered, in addition to the normal and aberrant pro-
viruses, unintegrated circular viral DNAs, 1- and 2-LTR 
circles and auto-integrants in the experiments done with 
the WT IN vector in the presence of sub-optimal doses 
of the EVG (Table 1). Some of these circular forms of the 
viral DNA had aberrant structures; the numbers of the 
normal and aberrant circular forms recovered in each of 
the experiments are given in the tables. As expected, the 
ratio of the unintegrated forms of the viral DNA to the 
integrated forms went up when the infections were done 
in the presence of EVG. These results are similar to the 
results we obtained with sub-optimal RAL (10).
We recovered a larger number of proviruses at the 
highest dose of EVG (IC75) than at the lower doses. This 
suggests that, for some reason, the recovery of the inte-
grated viral DNA was particularly efficient for this sam-
ple. Although we strive to do the experiments exactly the 
same way for each sample, there are steps in the proce-
dure (for example the ligation step which forms circular 
DNAs from the integrated proviruses) whose efficiency 
cannot be accurately monitored. Variation in the effi-
ciency of these steps can have a profound effect on the 
number of the proviruses that are recovered. For that rea-
son, the ratio of aberrant to normal proviruses is a better 
measure of the impact of the drugs on integration than is 
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a comparison of the absolute number of integrated and 
unintegrated viral DNAs recovered. In Table 1, the ratio 
of aberrant to normal proviruses ranged from ~1/15 to 
~1/5. With the exception of the data for the IC30, where 
the dataset was small, compared to the total number of 
samples recovered and sequenced, the data for all of the 
other EVG concentrations showed (using Fisher’s exact 
test) a statistically significant difference (p < 0.05) in the 
fraction of aberrant integrations compared with the no 
drug control. Although a larger fraction of the proviruses 
we recovered were aberrant at the higher drug concen-
trations, the absolute number of aberrant proviruses was 
relatively small, and the differences seen in the fraction of 
aberrant integrations at the different drug concentrations 
used were not statistically significant.
We analyzed the structures of the aberrant proviruses. 
A description of the defective proviruses isolated in the 
experiments described in Table  1 is given in Additional 
file  2: Table S1. In most cases, the aberrant proviruses 
have one end in which the viral DNA, and the junction 
to the host genome, appear to be normal, which supports 
our assumption that this end was appropriately inserted 
by IN. The aberrant end of the viral DNA was often, 
but not always, truncated. The aberrant viral DNA end 
could be joined either to additional viral DNA sequences 
(in either orientation), or to sequences from the host 
genome. Most commonly, the host DNA was duplicated 
where it was joined to the aberrant viral DNA end. How-
ever, instead of a short 5 bp repeat, in the aberrant pro-
viruses harboring a duplication of the host sequences, 
the repeats or duplications were usually much larger, 
and could be hundreds or thousands of bp long. Alter-
natively, there were deletions of the flanking host DNA, 
and less frequently inversions. There were, in some cases, 
insertions of host sequences from other chromosomes. 
In terms of their structure, the aberrant proviruses pro-
duced by infections done in the presence of suboptimal 
doses of EVG appeared to be quite similar to the aberrant 
proviruses produced by infection in the presence of sub-
optimal doses of RAL. We also recovered circular forms 
of viral DNA that have host sequences inserted between 
the LTRs, which do not appear to derive from proviruses. 
Viral DNAs of this type have been recovered before, in 
experiments done with mutants of an ASLV-based vec-
tor. We proposed that these circular DNAs derived from 
abortive integration events [29].
Drug resistance mutations in IN can cause aberrant 
integrations
If, as we have suggested, a suboptimal dose of an INSTI 
can block the integration of one end of the viral DNA, 
that could lead to aberrant integrations. This suggests the 
possibility that IN mutations that significantly reduce the 
activity of the enzyme could also cause similar aberrant 
integrations, even in the absence of an anti-IN drug. We 
tested three IN mutants, all of which reduced the suscep-
tibility of the virus (and IN) to RAL, and caused a reduc-
tion in the relative infectivity of the single-round HIV 
vector used in our assay system (Y143R, residual titer 
is 40–45  % of WT; N155H, ~40  % of WT, and G140S/
Q148H, 30–35 % of WT). The Y143R mutant specifically 
causes resistance to RAL; the other two mutants also 
cause cross-resistance to other INSTIs. We addressed 
two questions: (1) Would any of these three IN mutants 
cause aberrant integrations in the absence of an added 
INSTI?, and (2) Would the addition of a suboptimal dose 
of an INSTI affect (increase) the propensity of these three 
IN mutants to make aberrant integrations? Because the 
drug-resistant mutants are considerably less sensitive to 
inhibition by RAL, we used much higher concentrations 
of RAL as a suboptimal dose. The concentrations of RAL 
were chosen so that the level of infectivity of the mutants 
was reduced to match two of the decreases in infectivity 
in the experiments done with the WT vector (IC50 and 
Table 1 Recovery of integrated viral DNA from elvitegravir treated cells
* Data for the no drug control are from Varadarajan et al. [10]
** EVG IC50: 6.57 nM





















No drug* 0 99 0 7 (0) 0 (0) 1 (2) 120
IC14** 4 39 9.3 108 (21) 19 (5) 10 (56) 288
IC30 1 14 6.6 102 (31) 10 (8) 11 (58) 276
IC50 2 19 9.5 116 (18) 28 (14) 11 (47) 288
IC60 2 19 9.5 125 (11) 26 (10) 12 (52) 288
IC75 8 46 14.8 93 (25) 13 (13) 3 (57) 287
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IC75). We previously showed that we obtained similar 
results, in terms of RAL causing aberrant integrations, 
in a standard cell line (HOS) and in PBMCs [10]. Here, 
we tested the effects of one of the mutants (N155H) in 
the absence of any added drug in both HOS cells and 
PBMCs.
The Y143R mutation is RAL-specific; Y143 has a π–π 
interaction with the oxadiazole ring of RAL. This moiety 
is not present in the other approved INSTIs [30], and, for 
that reason, Y143R does not confer cross resistance to 
the other INSTIs. Although position 143 is near the IN 
active site, it is farther from the metal ions than the other 
resistance mutations that we tested (positions 140, 148, 
and 155; see Fig. 1). In the absence of any added RAL, we 
found aberrant integrations in infections that were done 
using the Y143R mutant; however, for the Y143R muta-
tion, the ratio of aberrant to normal integrations was 
relatively low (1/30), and the fraction of aberrant integra-
tions was not, when compared to infections done with 
WT IN in the absence of added RAL, statistically signifi-
cant. This ratio increased in the presence of a subopti-
mal dose of RAL (~1/8 at the IC50 and ~1/10 at the IC75) 
(Table 2; Additional file 2: Table S2), and the fraction of 
aberrant proviruses obtained at both the IC50 and IC75 
were significant (p  <  0.006 and p  <  0.009, respectively), 
when compared to the control done with WT IN in the 
absence of any added drug. This is important because 
the Y143R mutation raised the IC50 for RAL substan-
tially, (IC50 425 nM, see Table 2), and doses of RAL that 
would be optimal for WT would be suboptimal for the 
Y143R mutant. A description of the defective proviruses 
isolated in the experiments described in Table 2 is given 
in Additional file 2: Table S2. In all of these experiments, 
the number of aberrant integrations was small. Although 
the data suggest that a suboptimal concentration of RAL 
appears to increase the propensity of the Y143R mutant 
to make aberrant integrations, the differences in the frac-
tion of integration sites that were aberrant for the Y143R 
mutant, comparing the presence and absence of RAL, 
were not statistically significant.
The N155H mutation lies near the sites where the 
metal ions are bound in the IN active site, and near the 
3′ end of the viral DNA. In the absence of any added 
RAL, the ratio of aberrant to normal integrations is 
about 1 to ~7 in infected HOS cells (Table 3); this differ-
ence is statistically significant (p = 0.002). A description 
of the defective proviruses isolated in the experiments 
described in Table 3 is given in Additional file 2: Table S3. 
Adding RAL at the IC50 concentration caused an increase 
to ~1/4. There may have been a modest increase in the 
fraction of aberrant proviruses at IC75 (~1/3); however, 
because the sample size is small, this apparent difference 
Fig. 1 RAL bound in the IN active site. Model showing raltegravir 
(RAL) bound in the active site of HIV-1 IN (see Hare et al. [9]). The 
bound form of RAL (green) chelates the Mg2+ ions at the active site 
through the diketo motif. The oxidazole ring and benzyl moiety 
of RAL interact, through π–π stacking, with Y143 (teal) and the 
penultimate cytosine (magenta) at the 3′ end of the viral DNA strand, 
respectively. Binding of RAL causes the adenosine (magenta) to move 
away from IN active site (side chains are white), which inhibits the 
strand transfer reaction. Residues that are mutated in resistant forms 
of IN are shown (side chains colored teal), and the letter designating 
the mutant amino acid is indicated in red
Table 2 Recovery of integrated viral DNA from cells infected with the IN mutant Y143R
RAL IC50: 425 nM





















No drug 2 62 3.1 94 (19) 12 (9) 9 (55) 288
RAL IC50 4 35 10.2 87 (7) 23 (18) 8 (75) 288
RAL IC75 4 42 8.7 83 (17) 40 (11) 4 (61) 288
Page 7 of 10Varadarajan et al. Retrovirology  (2016) 13:71 
was not statistically significant. To be sure that the IN 
mutants would also cause similar aberrant integrations in 
PBMCs, we infected these cells with the N155H mutant. 
The ratio of aberrant to normal integrations appeared to 
be lower in the absence of any added drug in the PBMCs 
(~1/10). When these data were compared to data from a 
control experiment in which PBMCs were infected with 
the WT virus (10), the difference was statistically signifi-
cant (p = 0.006). Although the ratio of aberrant to nor-
mal integrations appeared to be slightly lower in PBMCs 
than in HOS cells (~1/7), this difference was not statisti-
cally significant.
The Q148H mutation is also near the two metal ions at 
the IN active site, and the 3′ end of the viral DNA. The 
G140S mutation is adjacent to Q148H (Fig.  1). In the 
absence of any added drug, this double mutation also 
caused aberrant mutations; the ratio of aberrant to nor-
mal mutations in HOS cells was ~1/11 (Table 4); this is 
significant compared to the no drug control (p = 0.007). 
A description of the defective proviruses isolated in the 
experiments described in Table  4 is given in Additional 
file 2: Table S4. The ratio was similar at the IC50 (~1/13), 
and the ratio appeared to increase to ~1/6 at the IC75; 
again, the numbers of aberrant integrations are relatively 
small, and the differences seen for this mutant in the pres-
ence and the absence of added drug were not statistically 
significant. As expected, we also recovered unintegrated 
circular viral DNAs when cells were infected with viruses 
that carried mutant forms of IN (Tables 2, 3, 4).
Discussion
It appears to be relatively easy to (partially) disrupt the 
HIV-1 integration process in ways that produce aber-
rant integrations. If the integration reaction is completely 
blocked, viral DNA is almost never inserted into the host 
genome. However, as has already been discussed, it is 
possible to create conditions under which IN can insert 
only one end of the viral DNA. When this happens, host 
enzymes insert the second viral DNA end into the host 
genome with an efficiency that can be as high as 30 % of 
the rate at which a normal viral DNA end can be inserted 
by IN [12]. This produces what at first appears to be a 
complex array of host/virus DNA junctions, in which 
the viral DNA sequences are often (but not always) trun-
cated. The host and virus DNAs at these aberrant junc-
tions can be duplicated, deleted, inverted, and sequences 
from other chromosomes can be brought in.
However, the data suggest that there is a single under-
lying theme, and that a relatively simple set of pro-
cesses, which can be catalyzed by well-characterized 
host machinery, can account for all of the aberrant pro-
viruses: (1) The unintegrated 3′ end of the viral DNA 
is used by a host DNA polymerase to prime DNA syn-
thesis; nearby DNA sequences (either host or viral) are 
Table 3 Recovery of integrated viral DNA from cells infected with the IN mutant N155H
RAL IC50: 297 nM




















 No drug 5 36 12.2 82 (8) 27 (17) 4 (66) 287
 RAL IC50 6 26 18.7 75 (15) 55 (23) 6 (43) 288
 RAL IC75 2 6 25 93 (7) 57 (22) 5 (55) 288
PBMC
 No drug 10 103 8.8 82 (4) 15 (1) 0 (36) 285
Table 4 Recovery of integrated viral DNA from cells infected with the IN mutant G140S/Q148H
RAL IC50: 4.25 µM





















No drug 5 56 8.2 72 (17) 25 (5) 7 (50) 288
RAL IC50 5 66 7 38 (6) 32 (15) 9 (85) 288
RAL IC75 7 45 13.5 56 (10) 38 (13) 6 (72) 288
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used as the template, and (2) The host polymerase cre-
ates an extended DNA (which is attached to the 3′ end of 
the viral DNA) that has homology to nearby host DNA. 
Homologous recombination creates aberrant proviruses 
that, collectively, correspond to the structures of the 
aberrant proviruses we have mapped.
First, the 3′ end of the viral DNA is used to prime DNA 
synthesis. Because integration takes place in the nucleus 
of the infected cell, there are a number of host DNA poly-
merases present that are involved in the repair of the host 
genome [31–33]. Because these host DNA polymerases 
cannot initiate DNA synthesis de novo, they require, in 
addition to the viral DNA, which is used as the primer, a 
template. This explains the fact that, at the aberrant end 
of the viral DNA there is usually, although not always, 
a short segment that is homologous to the appended 
DNA sequence. In the search for a homologous tem-
plate sequence on which to prime, the viral DNA end 
can be truncated by the host DNA polymerase (or an 
ancillary factor). Although it is common for the host 
DNA polymerase that is extending the 3′ end of the viral 
DNA to copy an adjacent host sequence, it is also pos-
sible for the polymerase to copy a segment from either 
strand of the viral DNA. Thus the polymerization reac-
tion appends whatever host or viral DNA sequence is 
copied onto the 3′ end of the viral DNA. This process is 
not confined to copying a single viral or host template, 
and multiple sequences can be appended to the 3′ end of 
the viral DNA. For the viral DNA to be successfully inte-
grated, the polymerization reaction must copy sequences 
on the chromosome in which IN made the initial inser-
tion. Once a segment near the original integration site 
has been copied, homologous recombination can join 
the aberrant DNA end to the host genome. It should be 
clear that this homologous recombination can take place 
on either side of the initial IN-mediated event. Thus the 
host-mediated insertion reaction can lead to a deletion 
in the flanking host DNA if it takes place on one side of 
the initial IN-mediated integration event; if it takes place 
on the other side, it will cause a duplication of the flank-
ing host DNA, as was shown in experiments done using 
ASLV-based vectors [11, 12, 34].
Although we have now found three different sets of 
circumstances that can cause a similar set of aberrant 
integrations, here too, there is a single, straightforward, 
underlying theme. In the initial experiments, done using 
an ASLV vector, we made mutations in the viral genome 
that led to the synthesis of linear viral DNAs that had one 
end that was not a good substrate for IN. To our surprise, 
this had, in some cases, only a modest impact on the titer 
[12]. As was discussed earlier, we showed, by isolating the 
resulting proviruses that, if one end of the viral DNA was 
inserted into the host genome by IN, the other could be 
efficiently inserted into the genome by the host machin-
ery. In thinking about the effects of a suboptimal dose of 
an INSTI, we thought it possible that a suboptimal dose 
of an INSTI could mimic the effects of a viral DNA with 
a bad end: one end of the viral DNA could be inserted by 
IN, the other (blocked by the INSTI) would be inserted 
by the host machinery. We previously showed that sub-
optimal doses of RAL could produce aberrant integra-
tions that are similar to those produced by making viral 
DNAs with one bad end. We now show that EVG has the 
same effect, and it seems very likely that a suboptimal 
dose of any INSTI will produce similar results.
In both of these scenarios, there is a considerable differ-
ence in the ability of IN to insert the two different ends of 
the viral DNA; one end will be inserted with the normal 
high efficiency, the other very poorly, or not at all. For 
that reason we were curious about the effect of reduc-
ing the overall activity of IN on aberrant integrations. In 
this case there would be a similar reduction in the abil-
ity of IN to insert each of the two ends of the viral DNA. 
Experiments done using some of the common RAL-
resistant mutants, which are known to reduce the activity 
of IN, produced aberrant integrations in the absence of 
any added INSTI. These aberrant integrations appear to 
be very similar to those produced either by using a viral 
DNA with a bad end, or by using a suboptimal dose of 
an INSTI. This suggests that there is a relatively modest 
excess of IN enzymatic activity, relative to what is needed 
to carry out the integration of the two ends of the viral 
DNA, and that there is a limited time during which the 
integration reaction can take place.
One of the consequences of having an IN that carries 
resistance mutations is that these mutations raise the 
IC50 for the drug, making drug concentrations that are 
optimal against the WT virus suboptimal for the resist-
ant mutants. We show here that, although the mutations 
that confer resistance to RAL are capable of causing aber-
rant integrations in the absence of an added INSTI (RAL 
in our case), the addition of high levels of RAL appeared 
to increase the ratio of aberrant to normal integrations, 
although the numbers of aberrant integrations we recov-
ered was small, and the differences were not statistically 
significant. This means that, in a patient who is undergo-
ing treatment with an INSTI, the drug resistance muta-
tions would have two paths by which they would cause 
aberrant mutations (1) by affecting the enzymatic activity 
of IN and (2) by causing what would normally be an opti-
mal dose of the INSTI to be suboptimal.
It has long been thought that HIV proviruses, in con-
trast to the proviruses of a number of other retroviruses, 
do not integrate into places in the genome that can stim-
ulate the growth the infected cells. However, both we 
and others recently showed that HIV integration into 
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certain oncogenes (BACH2 and MKL2) can lead to the 
clonal expansion of the infected cells [13, 14]. In a mouse 
model, activation of the BACH2 gene by the integration 
of an MLV provirus can cause tumors [35]. Although a 
direct link between HIV integration and oncogenic trans-
formation has not been established, there is, in the litera-
ture, a report of a tumor which has an HIV integration 
in BACH2 [36]. Because there is only this one report, its 
significance is not yet clear. However, the available data 
suggest the possibility that HIV integration could poten-
tially lead to tumorigenesis. As we previously pointed 
out, the fact that the aberrant integrations that are caused 
by suboptimal doses of an INSTI, or, as we report here, 
by INSTI-resistance mutations even in the absence of an 
INSTI, is cause for concern. This concern is based on the 
observation that the aberrant integrations can involve 
substantial rearrangements of the host genome, includ-
ing duplications, deletions, inversions, and the insertion 
of sequences from other chromosomes. DNA rearrange-
ments in both BACH2 and MKL2 are known to play a 
role in human cancers [37–40]. If normal HIV integra-
tions in BACH2 and MKL2 can cause the clonal expan-
sion of the infected cells, it would seem that the sorts of 
aberrant integrations we have described are more likely 
to alter the expression of genes than are normal inte-
grations, which could have unwanted, and undesirable, 
consequences.
Conclusions
We previously showed that suboptimal doses of an IN 
inhibitor RAL caused aberrant integrations that included 
deletions, duplications, and transfer of genetic informa-
tion from one chromosome to another. We show here 
that a second IN inhibitor, EVG, can cause similar aber-
rant integration. More importantly, we also show that 
some IN inhibitor resistance mutations that reduce the 
enzymatic activity of IN can cause aberrant integrations, 
even in the absence of an inhibitor. At least two of the 
three clinically relevant drug resistant integrase mutants 
we tested, N155H and G140S/Q148H, which reduce the 
enzymatic activity of integrase, caused aberrant integra-
tions, even in the absence of any added drug. In addi-
tion, these drug resistant mutants increase the IC50 for 
anti-integrase drugs, and concentrations of the drugs that 
would be optimal against the WT virus are suboptimal 
for the mutants. Normal HIV integrations into the onco-
genes BACH2 and MKL2 can cause the clonal expansion 
and proliferation of the infected cells, and rearrange-
ments of BACH2 and MKL2 can cause cancer in humans. 
For these reasons, we suggest that there should be con-
cern about therapies, and mutations in HIV, that can lead 
to aberrant integrations that involve deletions, duplica-
tions and rearrangements of the host DNA.
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